Tag: ocrelizumab
Our application to the Essential Medicines List
Efforts to improve access to MS treatments continue
First treatment for early primary progressive MS approved in Europe
The European Commission has approved the first disease-modifying therapy, ocrelizumab, for early primary progressive MS (PPMS).
European Medicines Agency recommends market authorisation for ocrelizumab (Ocrevus) in EU
The EMA has recommended that ocrelizumab (Ocrevus), the first disease-modifying treatment for primary progressive MS (PPMS), be prescribed for adults with early primary progressive MS
First treatment licensed for primary progressive MS in the US
Ocrelizumab has been approved as a treatment for both relapsing and primary progressive MS in the US
Research highlights of 2016
Professor Alan Thompson highlights some of 2016’s research discoveries in MS